An official website of the United States government
NIA has a long-standing commitment to the principles of open science to accelerate dementia research. As part of that pledge, we are pleased to announce that trial data and biosamples from the pivotal Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) Study, are now available for download and exploration by the scientific community. Although the results of the A4 trial demonstrated that the drug did not meet its primary endpoints , its early and sustained data and biosample sharing set a new precedent and will be discussed at the 2024 NIH Alzheimer’s Research Summit coming up Sept. 23-25.
Generating a wealth of dementia research data
Part of the Accelerating Medicines Partnership® Program for Alzheimer’s Disease , the A4 study was a multisite trial that tested whether the investigational anti-amyloid drug solanezumab would slow cognitive decline in the earliest stages of Alzheimer’s. The study was the first of its kind in individuals with preclinical Alzheimer’s (high levels of amyloid on brain scans but without cognitive impairment). A4 pioneered the sharing of screening data and biosamples from its nearly 1,200 participants within 12 months of enrollment, and the study team has continued to share them regularly with the scientific community for nearly five years.
So far, more than 1,500 requests for clinical data from the study have been approved, and the data have generated approximately 60 peer-reviewed research articles. Analyses of A4 screening data and biosamples have already provided new insights on disease biology, Alzheimer’s biomarkers in ancestrally diverse individuals, and gender differences in cognitive performance and neuroimaging biomarkers. The release of the full trial data are expected to lead to further insights into this devastating disease and possible avenues for prevention and treatment.
Check out the A4 data and register to attend the summit
If you want to tap into these exciting data for your research, visit www.a4studydata.org . Once you’re registered, keep an eye out for future waves of data, biosamples, and exploration tools, including neuroimaging and algorithms for characterizing novel biomarkers.
To learn more about the A4 study and its data, check out the 2024 NIH Alzheimer's Research Summit , Sept. 23-25; email Laurie Ryan ; or leave a comment below.
Alzheimer’s Disease and Related Dementias Clinical Research Data Sharing Scientific Resources 2024-09-18T00:00:00Z